Practical aspects of initiation and use of SGLT2 inhibitors: inpatient and outpatient perspectives

In today`s therapy of type 2 diabetes mellitus, SGLT2 inhibitors have taken their rightful place both due to positive hypoglycemic and outstanding cardiorenometabolic effects. Recent randomized clinical trials, such as DAPA HF, EMPEROR-Reduced EMPEROR-Preserved, show the benefits use in treatment patients with chronic heart failure without regard status mellitus so significantly expands range practice doctors various specialties. This review presents not only results most significant studies inhibitors, but also main approaches starting this class drugs situations, inpatient outpatient. addition, potential adverse events limitations associated are discussed detail, which must be into account when prescribing particular patient. The practical aspects inhibitors` prescription considered separately through prism safe perioperative postinfarction periods, well during other special conditions. Particular attention is paid monitoring physical general examination data laboratory instrumental tests, consideration will minimize best benefit for many cardiological, endocrinological nephrological patients.